| GTO ID | GTC3485 |
| Trial ID | NCT05914376 |
| Disease | Solid Tumor |
| Altered gene | IL-12 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | hV01 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Phase I Dose Escalation Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Biological Properties of Recombinant Human IL-21 Oncolytic Vaccinia Virus Injection (hV01) in Patients With Advanced Malignant Solid Tumors |
| Year | 2023 |
| Country | China |
| Company sponsor | Hangzhou Converd Co., Ltd. |
| Other ID(s) | hV01-ITu-101 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||
|
|||||||||